Many people with pancreatic cancer don't experience symptoms until the disease has ... the assay targets pancreatic ductal adenocarcinoma (PDAC), which makes up 80-90% of all pancreatic cancer ...

It can potentially lead to improved survival rates for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), the most prevalent and aggressive form of pancreatic cancer. Pancreatic ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

The new blood-based assay PAC-MANN-1 (protease activity–based cancer marker using magnetic nanosensor-1) identified pancreatic ductal adenocarcinoma (PDAC) across all stages with high ...

The firm's next-generation pancreatic cancer test looks for five biomarkers that are indicative of early-stage disease.

(A) Schematic workflow of sample collection for further single-cell RNA sequencing. (B) The hematoxylin and eosin staining and immunohistochemistry staining of tumor sample from P6. (C) UMAP plots ...